JPS61134325A - ハイブリツド抗体遺伝子の発現方法 - Google Patents

ハイブリツド抗体遺伝子の発現方法

Info

Publication number
JPS61134325A
JPS61134325A JP59254980A JP25498084A JPS61134325A JP S61134325 A JPS61134325 A JP S61134325A JP 59254980 A JP59254980 A JP 59254980A JP 25498084 A JP25498084 A JP 25498084A JP S61134325 A JPS61134325 A JP S61134325A
Authority
JP
Japan
Prior art keywords
gene
human
antibody gene
mouse
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP59254980A
Other languages
English (en)
Inventor
Akira Kudo
明 工藤
Yuji Nishimura
有史 西村
Yataro Ichikawa
市川　弥太郎
Takeshi Watanabe
武 渡辺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd filed Critical Teijin Ltd
Priority to JP59254980A priority Critical patent/JPS61134325A/ja
Priority to EP85115311A priority patent/EP0184187B1/en
Priority to US06/805,381 priority patent/US4935496A/en
Publication of JPS61134325A publication Critical patent/JPS61134325A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Abstract

(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。

Description

【発明の詳細な説明】 ａｌｌｌ工業上用分野 本発明は、マウス−ヒトハイグリッド抗体遺伝子の発現
方法に関するものである。更に詳しくは、マクス抗体遺
伝子の可変領域とヒト抗体遺伝子の定常領域とを結合、
させて得られたマウス−ヒトハイブリッド抗体遺伝子の
発現方法ｙｃｉｉＩするものである。
ｂ　従来技術 最近、抗体遺伝子の研究が進められ、哺乳動物、殊にヒ
トの抗体遺伝子におけるＨ鋼のＮ４明も行なわれつつあ
る。一般にＨ＠は抗原との結合部位である可変領域（Ｖ
領域）と、補体との結合や４１）定の細胞との相互作用
などの生理活性を有している定常領域（Ｃ領域）より形
成されていることよ（知られ℃いる（培凧館発行「現代
化学４１９８１年１１月号６２〜６８頁参照）。
一方、抗体遺伝子の核酸塩基配列及びそれの機能の解明
は、マウスの遺伝子について可成り進められており、七
の可父領域（Ｖ）には、■遺伝子、Ｄ遺伝子法びＪ遺伝
子がこの順序で並んで存在し、さらにＶ遺伝子の上流（
５′側末１ｔ）Ｋプロモーター機能を有する核酸塩基配
列が存在すること、またＪ遺伝子と定常領域（Ｃ）との
間に、転写効率を着しく増大させる機能を有する塩基配
列、つまりエンへンサーの存在が推測され【いる。
この二ンへンサーはＪ遺伝子の下流に存在し、未分化型
ではプロモーターが遠く離れているため転写効率を上げ
られないが、Ｖ−Ｊ遺伝子反びＶ−Ｄ−Ｊ遺伝子の組み
換えを起した時に発現型となりＶ遺伝子の上流のブーモ
ーターからの転写効率を上げる機能を有していると言わ
れている。
そしてマウスのＨ鎖遺伝子におけろエンハンサ−に関し
て、その塩基配列は、最近シャフナ−（Ｗｅｌｔ＠ｒ　
８ｃｈａｔｆｎｍｒ　）らが明らかにし発表している（
Ｃ・１１．Ｖｏｌ、　３３＝　７２９−７４０　Ｊｕム
ｙ１９８３参照）。
また利根用進氏らも同様にマウスのＨ鐵遺伝子の二ンノ
・ンサーの存在並びにその塩基配列を明らかにしている
（　０ｅ１１．　Ｍｏ１．３３゜７１７−−７２８．　
　Ｊｕｌｙ　１９８３参照）さらにデビット・バルチモ
７（Ｄ１マｌｄＢａｌｔｉｍｏｒ１　）らは、マウスの
Ｌ−綱の工ンハンナーの存在並びにその塩基配列を報告
している（　０ｅｌｌ、Ｍｏ１−３３．７４１−７４８
．　Ｊｕｌｙ　１９８３参照）。
このように、マウスの）ＩＩＩＩＫおよびＬ鎖の遺伝子
に関しては、可変領域（Ｖ）、定常領域（Ｃ）の両領域
に含まれる種々の遺伝子単位をはじめ、プロモーター、
エン／Ｓノナ−などの稙々の機能を有する単位の存在が
明らかにされ、また一部はそれらの核酸塩基配列が決め
られている。
一方ヒト抗体遺伝子のＨ鎮については、その構成遺伝子
及びその機能が次第に明らかにされつつあったが、二ン
ノ）ンナーの存在は推測されていたにすぎず、その全核
酸塩基配列入びその機能を発現させる核酸塩基配列単位
については未だ知られてはいなかった。
しかしながら、ごく最近になって、ラビットら（Ｔ、Ｈ
，Ｒａｂｂｉｔｔｓ　ｓｔｔ、　ｍｌ、）および利根用
進らはそれぞれ独立にヒト抗体遺伝子のＨ鎖中のエンハ
ンナーの核酸塩基配列を報告している（　Ｎａｔｕｒｅ
、　ｖｏｌ、　３０６＊　８０６−８０！Ｌ　２２／２
ａ。
Ｄｅｃｌｍｂｕ　１９８３　ａｎｄＮａｔｕｒ＠ｖｏｌ
Ｊｏ　Ｌ　３３４−３４（Ｌ　２６　Ｊａｎｕａｒｙ　
１９８４参照）。
従来ヒトモノクルーナル抗体としては、抗原にｑＩｆ！
Ａ的なものは得られていない。一方、マウスに関しては
抗体ＩＷ＋異性のモノクシ−ナル抗体は比較的よく得ら
れているが、これを臨床を目的して用いようとした場合
にはその抗原性が問題であった。
そこで本発明者らＧ’！、Ｉ・イブリッド抗体遺伝子、
殊にマクスの抗体遺伝子とヒトの抗体遺伝子との結合に
よって発現し得るハイブリッド抗体遺伝子について研究
を進めた結果、本発明方法に到達した。
Ｃ発明の構成 すなわち、本発明はマウス抗体遺伝子の可変領域（Ｔ／
＠域）とヒト抗体遺伝子の定常領域（Ｃ領域）とを遺伝
子で結合して得られたマクス−ヒト八イブリッド抗体遺
伝子をミエローマ細胞中に岨み込み、ミエローマ細胞中
で該ハイブリッド抗体通、伝子を発現させることを特徴
とするマクス−Ｌトハイグリッド抗体遺伝子の発現方法
である。
か〜る本発明方法によれば、マウスのＶ領域とヒト００
領域のそれぞれの抗体遺伝子を遺伝子部分（すなわち蛋
白をコードしていない部分）で結合させて、ハイブリッ
ド抗体遺伝子を得、これをミエローマ細胞甲に岨み込む
ことくよりミエー−マ、ｉ６ａ中でハイブリッド抗体遺
伝子が発現される。該マクス−ヒト抗体遺伝子としては
、マウス抗体遺伝子の可変領域（Ｖ）とヒト抗体遺伝子
の定常領域（Ｃ）トカヒトエン・−ンサーを介して遺伝
子部分で結合したものであるのを用いるのが有利である
。その際、使用されるミエローマ細胞としては、哺乳動
物由来のミニシーマ細胞であるのが好ましく、特にマウ
スミエローマ、うットミエーーマ、ヒトミ二一−マが有
利テ＆る。
本発明において、マウス−ヒトハイブリッド抗体遺伝子
をミエローマ細胞中に組み込むには、機々の方法が採用
できるが、飼えば形成したマクス−ヒトハイブリッド抗
体遺伝子を動物細胞発現型ベクターに挿入してプラスミ
ドを得、これを例えば大腸菌などに形質転換し、得られ
た形質転換体をミエー−マ細砲とプロトプラスト融合さ
せることにより行うことができる。
次に本発明者らが行ったハイブリッド抗体遺伝子の作成
並びにその発現の実験九ついて詳細に説明する。
作成）； 抗ヒト急性白血病リンパ種抗体Ｈ鎮遺伝子（７，９Ｋｂ
）をベクｐ−ｐ、ＢＲ３２２のＢｃａＲＩｔイトに挿入
したプラスミドｐＢＲ−ＮＬ−１−ＨのＨＩＩＶ領域全
域を含むＰｌｃｏＲＩ　−Ｂａｍ　ＨＩ　　７ラグメン
ト（約２．７Ｋｂ）を制限酵素切断のあと、アガー−ス
ミ気泳動によつ【分離し精製した。
一方、ベルブらが開発したベクターｐＳＶ２−ｇｐ　ｌ
　（ＲｓＯ，Ｍｕｌｌｌｇａｎ　　　ａｎｄ　　Ｐ、Ｂ
ｌｒｇ＋　　　ｆ’ｒｏｃｓ　　Ｎａｔｈ　　ａ人ｃｓ
ｄ、８ｃ１．、　　Ｕ、８．Ａ、、　　７８（４）２０
７２（１９８１）参照〕を制限酵素ＢａｍＨＩ−Ｈｐａ
Ｉで切断し、ｌｃｏｇｐｔ遺伝子を含む約５．３Ｋｂの
線状ベクター遺伝子を分離し精製した（このベクター遺
伝子を１７ラグメントー１１と略称する）。
先に得たｐＢＲ−ＮＬ−１−ＨＩｉｃｏＲＶ−ＢａｍＨ
Ｉの７ラグメント（約２．７Ｋｂ）と前記ｐｓｖｚ−ｇ
ｐｔ　ＯＢａｍ　ＨＩ　−Ｈｐ　ａ　［のフラグメント
−１（約５．３　Ｋｂ　）とを′ｒ４リガーゼ（宝酒造
社製）を用いてライダーク１ンし、次いで制限酵素Ｂａ
ｍＨＩで切断し、ＮＬ−１−ＨのＶ領域約２．７　Ｋｂ
　を含む線状ベクター遺伝子（約８．ＯＫｂ　’）を得
、分離し精製した（このベクター遺伝子を％７ラグメン
トー２′と略称する）。
また、ヒト抗体遺伝予約２１　Ｋｂ　を含むプラスミド
ｐｓｖｚ−ＨＩＧＩから制限酵素ＭｌｕＩ（宝酒造社製
）で切断し、ヒトエン八ンサー瓦びＯｒを含む遺伝予約
１７Ｋｂのフラグメントを得、分離し精製した。この約
１７Ｋｂのフラグメント罠モレキュラークローニンｆ　
（Ｍｏ１ｅｃｕｌ訂０１ｏｎｌｎｇ＋　Ｔ、Ｍａｎｉａ
ｔｌａ　ｅｔ　ａｉＩＯｏｌｄ　８ｐｒｉｎｇ　Ｈａｒ
ｂｏｒＬａｂ、　１９８２　）の方法に準じ、ＢａｍＨ
Ｉ　　リンカ−（宝酒造社製）を付与した（これを１フ
ラグメント−４′と略称する）。
このフラグメント−４と先に得たフラグメント−２とを
Ｔ４リガーゼを用いてライゲーションし、ＴＩＬＫ大腸
ｉ［ｄｏｌｏｏｏに形質転換してヒトエン八ンサー（ｇ
ｈ）を介してＶ領域がマウス由来のもの、０領眠がヒト
由来のものであるハイブリッド抗体遺伝子を得た（この
遺伝子を’　ｐＭＨ−１’と略称する）。上記遺伝子ｐ
ＭＨ−１を得る系統図を図１に示した。
作成）； しト抗体Ｈ鎖遺伝子約２１　Ｋｂを含むプラスミドｐ８
Ｖ２−ＨＩＧＩを制限酵素Ｂａｍ　ＨＩで切断し、ヒト
エン八ンサー（Ｒｈ）及びＯｒ　を含む約１４Ｋｂのフ
ラグメントな常法により得た。
このフラグメントな先のフラグメント−２とで４リガー
ゼを用いてライダーシコンした後、大腸菌ＭＯＩＯＧＯ
に形質転換して、■領域がマウス由来であり、０領域及
び工ンハンナーがヒト由来のハイブリッド抗体遺伝子を
得たくこの遺伝子な′″ｐＭ）ｉ−２’と略称する）。
この遺伝子ｐＭＨ−２を得る系統図を図１に示した。
作成）； 前記プラスミドｐＢＲ−ＮＩ、−１−Ｈを制限酵素１！
ｆｃｏＲＶ、　ＢｃｏＲＩで切断し、マウスＨ鎖Ｖ領域
の全域とマウスエンハンサ−（Ｆｉｍ）を含む約４．７
Ｋｂのフラグメントを常法により得た。
次に前記ベクターｐａＶ２−ｇｐｔを制限酵素１ｃｏＲ
Ｉ、Ｈｐ　ｍ　Ｉで切断し、Ｂｃｏ’ｇｐｔ遺伝子を含
む約４．５Ｋｂのフラグメントな得、分離し精製した。
かくして得られたフラグメントと先のマクスＶ遺伝子の
７ラグメント（約４．７１Ｃｂ）とをＴ４リガーゼを用
いてライダージョンし、次いで制限酵素ＦｉｃｏＲＩで
切断し、ＭＬ−１−ＨのＶ領域約４．７　Ｋｂを含む線
状ベクター遺伝予約９．２　Ｋｂを得、これを分離し精
製した（これを１フラグメント−３′と略称する）。
また、ヒト抗体Ｈｍ遺伝子約２　ｌ　Ｋｂを含むプラス
ミドｐ８Ｖ２−ＨＩＧＩから制限酵素ＭｌｎＩで切断し
、ヒトエンハンサ−（ｌｈ）＆びＯｒを含む約１７Ｋｂ
の７ラグメントな得、分離して精製した。この約１７Ｋ
ｂの７ラグメントく前記と同様のモレキュラー・クロー
ニングの方法に準じて、Ｆ１６０ＲＩＩＪンカー（宝酒
造社製）を付与した（かくして得た７ラグメントを１７
ラグメントー５′と略称する）。
この、フラグメント−５と前記フラグメント−３とをＴ
４リガーゼを用いてライゲーションし鬼ヒト及びマウス
のエンハンサ−、マウス由来のＶ領域、ｈ）由来の０領
域を有するへイブリッド抗体遺伝子を得たくこの遺伝子
を’　ｐＭＨ−３’と略称する）。この遺伝子ｐＭＨ−
３を得る系統図を図ＩＫ示した。
作成）； 前記プラスミドｐＢＲ−ＮＬ−１−Ｈな制限酵素Ｆｆｃ
ｏＲＶ−ＢａｍＨＩで切断し、マウスのＶ遺伝子全域を
含む約２．７Ｋｂのフラグメントな得、分離して精製し
た。次にこの７ラグメントのＢｃｏＲＶｍＫｇｃｏＲＩ
　１７　ｙ、ｅ−（宝酒造社製）を付与し１ｃｏＲＩ−
Ｂ蟲１■約２．７１Ｃｂのフラグメントを得た。
一方、前記ベクターｐ８Ｖ２−ｆｐｔを制限酵素Ｋｃｏ
ＢＩ　　ＢａｍＨＩで切断し、ＢｃＯｇｐｔ　　遺伝子
を含む線状ベクター４．６　Ｋ　ｂを得、分離して精製
した。このベクターと前記ＢｃｏＲＩ−ＢａｍＨＩ約２
．７　Ｋ　ｂの７ラグメントとをＴ４リガーゼを用いて
ライダージョンし、次いで制限酵素ＢａｎＨＩで切断し
、ＮＬ−１−ＨのＶ領域遺伝子を含むベクター遺伝予約
７．３　Ｋ　ｂを得た（これを１フラグメント−６１と
略称する）。
このフラグメント−６と前記実施例１で得たヒトエンハ
ンサー（ｌａｔｈ）２ＬびＯｒを含むフラグメント−４
とをで４リガーゼを用いてライダージョンし、次いで大
腸１１Ｍ０ＩＧＯＯＫ形質転換し、ヒトエンハンサ−（
旧０を介して、マウス由来のｖ領域、ヒト由来のＯ領域
を有するハイブリッド抗体遺伝子を得た（この遺伝子を
’ｐＭＨ−４’と略称する）。この遺伝子ｐＭＨ−４を
得る系統図を図２に示した。
作成）； 前記プラスミドｐＢＲ−ＮＬ−１−Ｈな制限酵素Ｂａｍ
ＨＩ−ｆａｃｏＲＩで切断し、マウスエン／Ｓフサ−（
１ｍ）を含む約２Ｋｂのフラグメントを得、分離して精
製した。こ°の約２Ｋｂのフラグメントを前記実施例３
で得たフラグメント−５とをＴ４リガーゼを用いてライ
ダージョンし、次いで制限酵素ＢａｍＨＩで切断して、
マウスとヒトのエンハンサ−及びヒトＯｒを育する約１
３ＫｂのＢｍｍＨＩ７ラグメントを得た。このＢａｍＨ
１７ラグメントを前記実施例４で得たフラグメント−６
とで４リガーゼを用いてライダージョンし、次いでこれ
を大腸１１１Ｍ０１０００に形質転換し、マウスとヒト
のエンハンサ−を介して、マウス由来のＶ領域、ヒト由
来のＯ領域を有するハイブリッド抗体遺伝子を得たくこ
の遺伝子を’　ｐＭＨ−５’と略称する）。この遺伝子
ｐＭＨ−５を得る系統図を図２に示した。
前記実施例１〜５で得られたへイブリッド抗体遺伝子Ｐ
ＭＨ−１〜ＰＭ）ｔ−５のそれぞれを大腸菌ＭＯ１００
ＯＫ形質転換し、得られた形質転換体とマウスミエロー
マＪ５５８Ｌ反びＮ８−１とのプロトプラスト融合くよ
って、前記各遺伝子ｐＭＨ−１〜ｐＭＨ−５をマウスミ
エー−マＪ５５８Ｌ汰びＮ８−１細砲に岨み込んだ。そ
れぞれの細胞なＲＰＭＩ完全培地中４８〜７２時間成育
させた。しかる後、抗ヒ）ＩｇＧ抗体を使用して蛍光染
色をして、ヒ）ＩｇＧ−Ｈ鎖の発現を調べた結果、遺伝
子ｐＭＨ−１、ｐＭＨ−２反びＩ）ＭＷ−４を岨み込ん
だ細胞にはそれぞれ強い発現が認められ、一方、遺伝子
ｐＭＨ−３及びｐＭＨ−５を組み込んだ細胞には比較的
弱い発現が観察された。
また、それぞれの細胞からＲＮ人を抽出し、得られたそ
れぞれの２０　、ｇを用い、マウスＶ遺伝子ｐａａ−Ｎ
Ｌ−１−Ｈの制限酵素１３ａｍＨＩ−ＰマＵ厘の７ラグ
メント入びヒト０遺伝子ｐｉ９Ｖ２−、ＨＩＧｌの０Ｈ
−ＯＨ１を會む制限酵素ＰｓｔＩのフラグメントでノー
ザンへイプリダイゼション（ｎｏｒｔｈｅｒｎ　ｈｙｌ
＋ｒｉｄｌ１ｍｔ１ｏａ　）を行った結果、遺伝子ｐＭ
Ｈ−１、ｐＭＨ−２ＪＬびｐＭＨ−４を岨み込んだ細胞
には強い発現が認められ、一方、遺伝子ｐＭＨ−３瓦び
ｐＭＨ−５を組み込んだ細胞には比較的弱い発現が認め
られた。本実施例６における前記発現の程度は、マウス
ミエローマＪ５５８Ｌ＆びＮ８−１のいずれにおいても
同じ傾向を示した。
また前記遺伝子ｐＭＨ−４をマウスミニ一マＪ５５８Ｌ
にプートプラスト融合によって４人し、選択培地中で２
遍間培養後、形質転換体を得た・得られた形質転換体か
らｒｎａＮ人を抽出しＮＬ−１のＶ遺伝子及びＯｒｌを
ブーープとしてノーザンハイグリダイゼーションを行っ
たところ、１．７　Ｋｂ　Ｋ５ｉ５全な分易型のｍＲＮ
人のＨ鎖を得た。
３８ｓ−メチオニンを用いて内部標識化（Ｉｎｔｅｒｎ
ａ１１１マｅ鳳）を行ない、イムノプレテイフイケーシ
コンを行った後、８Ｄ８−ＰＡＧｉｌ（ポリアクリルア
ミド電気泳動）Ｋかげた。その結果、培−養上清中にＨ
２Ｌ２形でＨｉｌｌｌ遺伝子が存在していることが６ｍ
認された。
また、サザーンハイプリダイゼーションによって、ハイ
ブリッド遺伝子の検出を試みたところ、細＠ｉ個当り平
均的０．５：ｆピーのハイブリッド遺伝子の存在が確認
された。
【図面の簡単な説明】
図１は、本発明の実施例において、ハイブリッド抗体遺
伝子ｐＭＨ−１〜ｐＭＨ−３を得る系統図を示したもの
であり、図２はハイブリッド抗体遺伝子！ＩＭＨ−４Ｊ
ＬびｐＭＨ−５を得る系統図を示したものである。

Claims (1)

  1. 【特許請求の範囲】 １　マウス抗体遺伝子の可変領域（Ｖ領域）とヒト抗体
    遺伝子の定常領域（Ｃ領域）とを遺伝子で結合して得ら
    れたマウス−ヒトハイブリッド抗体遺伝子をミエローマ
    細胞中に組み込み、ミエローマ細胞中で該ハイブリッド
    抗体遺伝子を発現させることを特徴とするマウス−ヒト
    ハイブリッド抗体遺伝子の発現方法。 ２　該マウス−ヒトハイブリッド抗体遺伝子はマウス抗
    体遺伝子の可変領域（Ｖ領域）とヒト抗体遺伝子の定常
    領域（Ｃ領域）とがヒトエンハンサーを介して遺伝子で
    結合して得られたものである第１項記載の発現方法。
JP59254980A 1984-12-04 1984-12-04 ハイブリツド抗体遺伝子の発現方法 Pending JPS61134325A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP59254980A JPS61134325A (ja) 1984-12-04 1984-12-04 ハイブリツド抗体遺伝子の発現方法
EP85115311A EP0184187B1 (en) 1984-12-04 1985-12-03 Mouse-human chimaeric immunoglobulin heavy chain, and chimaeric dna encoding it
US06/805,381 US4935496A (en) 1984-12-04 1985-12-04 Mouse-human chimaeric immunoglobulin heavy chain specific for the call antigen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59254980A JPS61134325A (ja) 1984-12-04 1984-12-04 ハイブリツド抗体遺伝子の発現方法

Publications (1)

Publication Number Publication Date
JPS61134325A true JPS61134325A (ja) 1986-06-21

Family

ID=17272540

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59254980A Pending JPS61134325A (ja) 1984-12-04 1984-12-04 ハイブリツド抗体遺伝子の発現方法

Country Status (3)

Country Link
US (1) US4935496A (ja)
EP (1) EP0184187B1 (ja)
JP (1) JPS61134325A (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6336796A (ja) * 1986-08-01 1988-02-17 Teijin Ltd マウス−ヒトキメラ抗体、それをコ−ドする発現型キメラｄｎａ配列、プラスミド及び細胞
JPS6336786A (ja) * 1986-07-31 1988-02-17 Teijin Ltd 抗体ｌ鎖発現型核酸塩基配列，プラスミド，細胞及びキメラ抗体ｌ鎖
JPS6344897A (ja) * 1986-04-14 1988-02-25 Dai Ichi Seiyaku Co Ltd ペプチド類の生産法
JP2008509084A (ja) * 2004-05-11 2008-03-27 アブゲノミクス コーポレイション Ｔ細胞死誘導エピトープ

Families Citing this family (711)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0536566A1 (en) * 1985-11-01 1993-04-14 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
DE3689123T2 (de) * 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
JPS62153300A (ja) * 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
EP0234592A1 (en) * 1986-02-28 1987-09-02 Teijin Limited Plasmid containing DNA fragment coding for human immunoglobulin G Fc region protein and use thereof for production of said protein
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE143052T1 (de) * 1986-07-07 1996-10-15 Centocor Inc Chimärisches murine-mensch-immunoglobulin, spezifisch für tumorassoziertes 17-1a antigen
NO873164L (no) * 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ES2102347T3 (es) 1987-02-20 1997-08-01 Genentech Inc Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
CA1341235C (en) * 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
IL88535A0 (en) * 1987-12-04 1989-06-30 Dana Farber Cancer Inst Inc Common acute lymphoblastic leukemia antigen
JP3095168B2 (ja) * 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
AU3342689A (en) * 1988-03-24 1989-10-16 Igen Incorporated Luminescent chimeric proteins
JPH02503867A (ja) * 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6004776A (en) * 1989-07-07 1999-12-21 Unilever Patent Holdings, B.V. Process for preparing a protein by a fungus transformed by multicopy integration of an expression vector
DE69031710T2 (de) * 1989-07-07 1998-03-05 Unilever Nv Verfahren zur herstellung eines proteins mittels eines durch mehrfachkopieintegrierung eines expressionsvektors transformierten pilzes
WO1991002743A1 (en) * 1989-08-23 1991-03-07 The General Hospital Corporation Non-human primate cd4 polypeptides, fusions thereof, dna encoding, and uses thereof
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
AU652997B2 (en) 1991-01-21 1994-09-15 Elan Pharmaceuticals, Inc. Test and model for alzheimer's disease
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5851787A (en) * 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5605811A (en) * 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
WO1995008336A1 (en) * 1993-09-22 1995-03-30 Nichols Institute Diagnostics Graves' ophthalmopathy associated antibodies, graves' ophthalmopathy orbital antigen, and methods of use thereof
DK0730643T3 (da) 1993-10-27 2001-05-14 Elan Pharm Inc Transgene dyr, som huser APP-allel med svensk mutation
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5614609A (en) * 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
DE69535830D1 (de) 1994-11-02 2008-10-16 Trophix Pharm Inc Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6248555B1 (en) 1995-08-31 2001-06-19 The General Hospital Corporation Genetic alterations related to familial alzheimer's disease
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US6716974B1 (en) 1996-05-31 2004-04-06 Maine Medical Center Research Institute Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
AU720890B2 (en) 1996-05-31 2000-06-15 National American Red Cross, The Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
DE69740057D1 (de) 1996-07-12 2010-12-30 Bristol Myers Squibb Co Transkriptionaler Intermediärfaktor 2
US5977319A (en) * 1996-10-21 1999-11-02 Cambridge Antibody Technology Limited Specific binding members for estradiol; materials and methods
SI1019500T1 (sl) 1997-01-15 2007-02-28 Yeda Res & Dev Proteini, ki vezejo receptor 1 za ifn, dna, ki jih kodira, in postopki za regulacijo celicnega odziva na interferone
ATE426018T1 (de) 1997-04-10 2009-04-15 Stichting Katholieke Univ Pca3, pca3-gene und verfahren zu ihrer verwendung
US6054567A (en) 1997-04-11 2000-04-25 The United States Of America As Represented By The Department Of Health And Human Services Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
DE69837085T3 (de) 1997-04-16 2012-01-12 Millennium Pharmaceuticals, Inc. Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen
EP2060631A3 (en) 1997-04-25 2009-07-15 Aquila Biopharmaceuticals, Inc. Characterization of granulocytic ehrlichia and methods of use
GB9710154D0 (en) * 1997-05-16 1997-07-09 Medical Res Council Detection of retroviruses
CA2206774A1 (en) 1997-06-16 1998-12-16 Rick E. Preddie "prionins", highly specific markers for noninvasive presymptomatic defection of tse diseases, and targets for therapeutic reagents to prevent and control tse diseases in animals and humans
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
JP2001520038A (ja) 1997-10-21 2001-10-30 ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ グラスゴー Ｐ３００／ｃｂｐのコアクチベーターであるｊｍｙ、ｊｍｙをコードする核酸、およびその使用
ATE276763T1 (de) 1998-07-13 2004-10-15 Univ Texas Verwendung von antikörper gegen aminophospholipide zur krebsbehandlung
EP2301947A3 (en) 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
DE19915057A1 (de) 1999-04-01 2000-10-19 Forschungszentrum Borstel Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
IL130225A0 (en) 1999-05-31 2000-06-01 Yissum Res Dev Co Novel uses of antibodies against ache and peptides thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
KR100942863B1 (ko) 1999-08-24 2010-02-17 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
ES2260059T3 (es) 1999-09-29 2006-11-01 Diagnocure Inc. Rna mensajero del pca3 en tejidos benignos y malignos de prostata.
US7892541B1 (en) 1999-09-30 2011-02-22 Tumor Biology Investment Group, Inc. Soluble epidermal growth factor receptor isoforms
ES2629683T3 (es) 1999-11-30 2017-08-14 Mayo Foundation For Medical Education And Research B7-H1, una nueva molécula inmunorreguladora
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
EP1714661A3 (en) 2000-05-19 2012-03-14 The Center for Blood Research, INC. Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
EP2251026A1 (en) 2000-06-08 2010-11-17 Immune Disease Institute, Inc. Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury
US6803211B2 (en) 2000-08-25 2004-10-12 Pfizer Inc. Methods and compositions for diagnosing and treating disorders involving angiogenesis
CA2417432C (en) 2000-09-01 2010-11-02 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
GB0022748D0 (en) 2000-09-15 2000-11-01 Allied Therapeutics Ltd Reducing the content of cells in a biological sample
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
JP4198990B2 (ja) 2000-10-18 2008-12-17 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 造血細胞のｅ−セレクチン／ｌ−セレクチンリガンドポリペプチドおよびその使用法
CA2427820A1 (en) 2000-11-01 2002-06-13 Elusys Therapeutics, Inc. Method of producing biospecific molecules by protein trans-splicing
CA2429722A1 (en) 2000-11-28 2002-06-06 Wyeth Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2002044419A2 (en) 2000-11-28 2002-06-06 Wyeth Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
CA2431861A1 (en) 2000-12-08 2002-06-13 Curagen Corporation Method of detecting and treating tuberous sclerosis complex associated disorders
US7445802B2 (en) 2000-12-26 2008-11-04 Yeda Research And Development Co. Ltd Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
US7261901B2 (en) 2001-01-31 2007-08-28 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
US7250172B2 (en) 2001-01-31 2007-07-31 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
EP1373499B1 (en) 2001-02-23 2017-09-20 Dana-Farber Cancer Institute, Inc. Hin-1, a tumor suppressor gene
EP2388590A1 (en) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, a receptor for B7-4, and uses thereof
EP2278013A1 (en) 2001-04-16 2011-01-26 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
GB0111628D0 (en) 2001-05-11 2001-07-04 Scancell Ltd Binding member
US7745398B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 and treatment of cancer
US7744882B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US7045605B2 (en) 2001-06-01 2006-05-16 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2002102973A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1432431B1 (en) 2001-10-04 2017-05-10 Genetics Institute LLC Methods and compositions for modulating interleukin-21 activity
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE10151511A1 (de) 2001-10-18 2003-05-08 Basf Lynx Bioscience Ag ee3-Proteinfamilie und zugrundeliegende DNA-Sequenzen
AU2002357770B2 (en) 2001-11-30 2008-07-31 Biogen Ma Inc. Antibodies against monocyte chemotactic proteins
CA2469306A1 (en) 2001-12-05 2003-06-19 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
DE60234713D1 (de) 2001-12-18 2010-01-21 Endocube Sas Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
WO2003054155A2 (en) 2001-12-19 2003-07-03 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
GB0130543D0 (en) 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
AU2002367317A1 (en) 2001-12-31 2003-07-24 Dana-Farber Cancer Institute, Inc. Psoriasin expression by breast epithelial cells
US7494655B2 (en) 2002-03-05 2009-02-24 Ramot At Tel-Aviv University Ltd. Immunizing composition and method for inducing an immune response against the β-secretase cleavage site of amyloid precursor protein
BRPI0308376B8 (pt) 2002-03-11 2021-05-25 Bayer Pharma Aktiengellschaft molécula de anticorpo anti-ed-b humana, seu uso e composição
GB0207533D0 (en) 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
ATE345504T1 (de) 2002-05-07 2006-12-15 Pasteur Institut Screeningverfahren für peptide, die die bindung von pp1c an bcl-2, bcl-xl und bcl-w proteine inhibieren
EP1549277A4 (en) 2002-05-22 2007-09-05 Cleveland Clinic Foundation INDUCING AND MAINTAINING COMPLEX TISSUE ALLOGRAFT TOLERANCE
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
EP2801616A1 (en) 2002-06-17 2014-11-12 Thrasos Innovation, Inc. Single domain TDF-related compounds and analogs thereof
ATE491725T1 (de) 2002-07-15 2011-01-15 Univ Texas Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
US7250551B2 (en) 2002-07-24 2007-07-31 President And Fellows Of Harvard College Transgenic mice expressing inducible human p25
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
AU2003256912A1 (en) 2002-08-16 2004-03-03 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
CN101044247B (zh) 2002-08-20 2011-06-22 千年药品公司 用于鉴定,评估,预防和治疗子***的组合物,试剂盒及方法
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7438918B2 (en) 2002-08-30 2008-10-21 University Of Iowa Research Foundation Lipid A deficient mutants of Neisseria meningitidis
EP2447278B1 (en) 2002-10-10 2015-04-08 Cornell Research Foundation, Inc. Novel immunogenic proteins of Leptospira
AU2003287622A1 (en) * 2002-11-06 2004-06-03 Fraunhofer Usa Expression of foreign sequences in plants using trans-activation system
US7683238B2 (en) * 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
EP2112229A3 (en) 2002-11-25 2009-12-02 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
AU2003298783B2 (en) 2002-11-26 2010-11-04 Abbvie Biotherapeutics Inc. Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
MXPA05005923A (es) 2002-12-06 2005-09-21 Millennium Pharm Inc Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma.
US8557957B2 (en) 2003-01-03 2013-10-15 Elizabeth Kornecki Methods of treating disorders by administration of F11 receptor antagonists
US20050265992A1 (en) 2003-01-03 2005-12-01 The Research Foundation Of State University Of New York F11 receptor (F11R) antagonists as therapeutic agents
CA2513675A1 (en) 2003-01-17 2004-08-05 The Johns Hopkins University Methods of identifying modulators of cellular glycosylation using gtrap3-18
WO2004070016A2 (en) 2003-02-03 2004-08-19 Fraunhofer Usa Inc. System for expression of genes in plants
WO2004070056A2 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
US20040180387A1 (en) 2003-03-13 2004-09-16 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
US20080081841A1 (en) 2003-03-20 2008-04-03 Badache Ali Materials and Methods for Modulating Cell Motility
JP2007524605A (ja) * 2003-04-03 2007-08-30 ピーディーエル バイオファーマ，インコーポレイティド インテグリンα５β１のインヒビターおよび組織顆粒化の制御のためのそれらの使用
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
WO2005026375A2 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
GB0313259D0 (en) 2003-06-09 2003-07-16 Consejo Superior Investigacion Magnetic nanoparticles
EP2508608A1 (en) 2003-06-09 2012-10-10 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
EP1514561A1 (en) 2003-09-10 2005-03-16 Philogen S.p.A. Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
KR20060120652A (ko) 2003-10-07 2006-11-27 밀레니엄 파머슈티컬스 인코퍼레이티드 난소암의 확인, 평가, 예방 및 치료를 위한 핵산 분자 및단백질
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005047475A2 (en) 2003-11-11 2005-05-26 Regents Of The University Of Minnesota Regulation of cell membrane-mediated effects
EP1714151A4 (en) 2004-01-21 2009-06-10 Fujirebio America Inc DETECTION OF PEPTIDES RELATED TO MESOTHELIN / MEGAKARYOCYTIC POTENTIAL FACTOR IN PERITONEAL LIQUID FOR THE ASSESSMENT OF THE PERITONEUM AND PERITONEAL CAVE
DK1766093T3 (da) 2004-02-06 2011-10-03 Univ Massachusetts Antistoffer mod clostridium difficile-toksiner og anvendelse deraf
EP1769068B1 (en) * 2004-02-20 2014-12-31 iBio, Inc. Systems and methods for clonal expression in plants
ATE498010T1 (de) 2004-03-01 2011-02-15 Immune Disease Inst Inc Natürliche igm-antikörper und inhibitoren davon
KR20060132006A (ko) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
ATE531388T1 (de) * 2004-03-24 2011-11-15 Abbott Biotherapeutics Corp Verwendung von anti-alpha5beta1-antikörpern zur hemmung der krebszellproliferation
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
GB0410627D0 (en) 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
CN103356636A (zh) 2004-05-23 2013-10-23 杰勒德·M·豪斯 Theramutein调节剂
CA2571218C (en) 2004-06-17 2015-11-03 William D. Carlson Tdf-related compounds and analogs thereof
WO2005123048A2 (en) 2004-06-21 2005-12-29 Proteome Sciences Plc Screening methods using c-abl, fyn and syk in combination with tau protein
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
CA2943949C (en) 2004-10-06 2020-03-31 Mayo Foundation For Medical Education And Research B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
PL1817345T3 (pl) 2004-11-09 2009-10-30 Philogen Spa Przeciwciała przeciwko tenascynie-C
WO2006132670A2 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
WO2006086469A2 (en) 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
CA2596986A1 (en) 2005-02-14 2006-08-24 Wyeth Use of il-17f in diagnosis and therapy of airway inflammation
RS59399B1 (sr) 2005-03-23 2019-11-29 Genmab As Antitela protiv cd38 za lečenje multiplog mijeloma
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
DK1871418T3 (da) 2005-04-19 2014-06-10 Seattle Genetics Inc Humaniserede anti-cd70-bindende midler og anvendelser deraf
EP1885396A2 (en) 2005-05-04 2008-02-13 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof
EP2305258A3 (en) 2005-05-31 2011-07-06 Duska Scientific Co Inhibition of neuronal damage
WO2006138553A2 (en) 2005-06-17 2006-12-28 Wyeth Methods of purifying fc region containing proteins
CA2614436C (en) 2005-07-07 2016-05-17 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
PL3248613T3 (pl) 2005-07-18 2022-04-19 Seagen Inc. Koniugaty β-glukuronid-linker-lek
ES2530265T3 (es) 2005-07-21 2015-02-27 Genmab A/S Ensayos de potencia de unión de una sustancia medicamentosa de anticuerpo a un receptor FC
WO2007117264A2 (en) * 2005-08-03 2007-10-18 Fraunhofer Usa, Inc. Compositions and methods for production of immunoglobulins
WO2007024940A2 (en) 2005-08-22 2007-03-01 Dana-Farber Cancer Institute, Inc. Mitochondrial localization of muc1
DK2497780T3 (en) 2005-09-20 2015-06-01 Thrasos Innovation Inc TDF-related compounds and analogs thereof
AU2006294481B2 (en) 2005-09-28 2012-12-20 Becton, Dickinson And Company Detection of lysophosphatidylcholine for prognosis or diagnosis of a systemic inflammatory condition
ES2526705T3 (es) 2005-10-25 2015-01-14 The Johns Hopkins University Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados
KR20140012160A (ko) 2005-11-01 2014-01-29 애브비 바이오테크놀로지 리미티드 바이오마커를 사용하여 강직성 척추염을 진단하기 위한 방법 및 조성물
CA2628238A1 (en) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
WO2007056618A1 (en) 2005-11-10 2007-05-18 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
US7807790B2 (en) 2005-11-14 2010-10-05 Metamol Theranostics, Llc Peptide sequence that promotes tumor invasion
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
US20070249014A1 (en) 2006-02-10 2007-10-25 Invitrogen Corporation Labeling and detection of post translationally modified proteins
US8124103B2 (en) * 2006-02-13 2012-02-28 Fraunhofer Usa, Inc Influenza antigens, vaccine compositions, and related methods
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
WO2007095320A2 (en) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Hpv antigens, vaccine compositions, and related methods
EP1854477B9 (en) 2006-03-16 2018-03-14 Dyax Corp. Peptides inhibiting plasma kallikrein for use in the treatment of ophthalmic disorders.
PL1999152T3 (pl) 2006-03-27 2013-05-31 Medimmune Ltd Element wiążący receptor GM-CSF
CA2647671A1 (en) 2006-03-31 2007-11-01 Massachusetts Institute Of Technology Treatment of tumors expressing mutant egf receptors
KR20090005315A (ko) 2006-04-05 2009-01-13 애보트 바이오테크놀로지 리미티드 항체 정제
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
EP2666479A3 (en) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Uses and compositions for treatment of juvenile rheumatoid arthritis
EP2019684A4 (en) 2006-04-20 2009-08-26 Jackson H M Found Military Med METHODS AND COMPOSITIONS BASED ON SHIGA TOXIN PROTEIN TYPE 1
US20080118978A1 (en) 2006-04-28 2008-05-22 Takashi Sato Anti-tumor agent
EP2035439A4 (en) 2006-06-05 2010-01-13 Cancer Care Ontario RISK ASSESSMENT FOR COLORECTAL CANCER
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
US8304384B2 (en) 2006-06-28 2012-11-06 Yeda Research And Development Co., Ltd Caspase-8 and inflammation, infection and wound healing
CN103316403B (zh) 2006-06-30 2017-05-24 艾伯维生物技术有限公司 自动注射装置
EP2046383B1 (en) 2006-07-04 2014-11-19 Genmab A/S Cd20 binding molecules for the treatment of copd
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
US20090203602A1 (en) 2006-09-01 2009-08-13 Cohava Gelber Compositions and methods for diagnosis and treatment of type 2 diabetes
GB0617429D0 (en) 2006-09-05 2006-10-18 Electrophoretics Ltd Markers of renal transplant rejection and renal damage
LT2081595T (lt) 2006-09-26 2019-07-10 Genmab A/S Anti-cd38 plius kortikosteroidai, plius nekortikosteroidinis chemoterapinis agentas, skirti vėžio gydymui
WO2008042436A2 (en) 2006-10-03 2008-04-10 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
JP5238710B2 (ja) 2006-10-19 2013-07-17 シーエスエル、リミテッド インターロイキン−１３レセプターアルファ１の高親和性抗体アンタゴニスト
CU23636A1 (es) 2006-11-01 2011-03-21 Ct Ingenieria Genetica Biotech Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)
JP2010510235A (ja) 2006-11-15 2010-04-02 ファンクショナル・ジェネティクス・インコーポレーテッド 抗ｔｓｇ１０１抗体およびウイルス感染の処置のためのその使用
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
PT2099823E (pt) 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2144613B1 (en) 2006-12-29 2018-03-21 OstéoQC Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
WO2008086002A2 (en) 2007-01-08 2008-07-17 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Slco1b3 genotype
WO2008091740A2 (en) 2007-01-22 2008-07-31 Genentech, Inc. Polyelectrolyte precipitation and purification of antibodies
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
EP2121745A2 (en) 2007-02-26 2009-11-25 Oxford Genome Sciences (UK) Limited Proteins
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
CA2679954A1 (en) 2007-03-05 2008-09-12 Cancer Care Ontario Assessment of risk for colorectal cancer
JP4842400B2 (ja) 2007-03-22 2011-12-21 ヘプテアズ・セラピューティクス・リミテッド Ｇタンパク質共役型受容体変異体及びその選択方法
ES2402171T3 (es) 2007-04-02 2013-04-29 Philogen S.P.A. El antígeno ED-A del fibrinógeno está asociado con la neovasculatura de las metástasis tumorales
EP2139916A1 (en) 2007-04-26 2010-01-06 Opsona Therapeutics Limited Toll-like receptor binding epitope and compositions for binding thereto
WO2008134643A2 (en) * 2007-04-28 2008-11-06 Fraunhofer Usa, Inc. Trypanosoma antigens, vaccine compositions, and related methods
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
CA2692933C (en) 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
CN103212072B (zh) 2007-07-25 2015-07-22 菲洛根股份公司 一种与肺癌和淋巴瘤相关的抗原
JP2010534685A (ja) * 2007-07-27 2010-11-11 ファセット バイオテック コーポレイション チロシンキナーゼ阻害剤およびインテグリンα５β１（ＣＤ４９Ｅ）に対する抗体を含む薬学的な組み合わせ
CN101848724A (zh) 2007-08-03 2010-09-29 奥普索纳医疗有限公司 Trl-2拮抗剂在治疗再灌注损伤和组织损伤中的用途
CN101820903A (zh) * 2007-08-20 2010-09-01 美国弗劳恩霍夫股份有限公司 预防性和治疗性流感疫苗、抗原、组合物和方法
WO2009039442A1 (en) 2007-09-21 2009-03-26 California Institute Of Technology Nfia in glial fate determination, glioma therapy and astrocytoma treatment
AU2008304615A1 (en) 2007-09-24 2009-04-02 Cornell University Immunogenic proteins from genome-derived outer membrane of leptospira and compositions and methods based thereon
GB0718843D0 (en) 2007-09-26 2007-11-07 Cancer Rec Tech Ltd Materials and methods relating to modifying the binding of antibodies
GB0719231D0 (en) 2007-10-03 2007-11-14 Oxford Genome Sciences Uk Ltd Protein
WO2009046388A1 (en) 2007-10-03 2009-04-09 United States Medical Research & Material Command Cr-2 binding peptide p28 as molecular adjuvant for dna vaccines
EP3783019A1 (en) 2007-10-30 2021-02-24 Philogen S.p.A. An antigen associated with rheumatoid arthritis
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
EP3211010A1 (en) 2007-12-21 2017-08-30 Medimmune Limited Binding members for interleukin-4 receptor alpha (il-4r) - 173
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
CA2710984C (en) 2007-12-28 2018-05-29 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
NO2842575T3 (ja) 2008-03-18 2018-02-24
US9527906B2 (en) 2008-04-18 2016-12-27 The General Hospital Corporation Immunotherapies employing self-assembling vaccines
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US20090291073A1 (en) * 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
US8741287B2 (en) 2008-06-18 2014-06-03 Abbott Laboratories PlGF-1 assay and kits and components thereof
EP2650014A2 (en) 2008-06-20 2013-10-16 Wyeth LLC Compositions and methods of use of ORF1358 from beta-hemolytic streptococcal strains
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
CA2738605A1 (en) 2008-09-24 2010-04-01 Luke Anthony O'neill Composition and method for treatment of preterm labor
KR102097887B1 (ko) 2008-09-26 2020-04-06 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
ES2659875T3 (es) 2008-10-10 2018-03-19 Children's Medical Center Corporation Vacuna de trímero de Env VIH-1 bioquímicamente estabilizado
BRPI0921286B8 (pt) 2008-11-05 2022-10-25 Wyeth Llc Composição imunogênica com múltiplos componentes para a prevenção de doença por estreptococos beta-hemolíticos (bhs).
RU2011121042A (ru) 2008-11-26 2013-01-10 Файв Прайм Терапеутикс, Инк. Композиции и способы регулирования экспрессии коллагена и актина гладких мышц посредством serpine2
AU2009323996A1 (en) 2008-12-03 2011-07-07 Institut Pasteur Use of phenol-soluble modulins for vaccine development
GB0823309D0 (en) 2008-12-19 2009-01-28 Univ Bath Functionalising reagents and their uses
US8580267B2 (en) 2008-12-19 2013-11-12 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
WO2010078526A1 (en) 2008-12-31 2010-07-08 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
US9527907B2 (en) 2009-01-07 2016-12-27 Philogen S.P.A. Antigens associated with endometriosis, psoriatic arthritis and psoriasis
AU2009336800A1 (en) 2009-01-07 2011-07-21 Philogen S.P.A. Cancer treatment
WO2010080985A1 (en) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
CA2750581A1 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
WO2010084327A2 (en) 2009-01-26 2010-07-29 Electrophoretics Limited Methods
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
JP2010213694A (ja) 2009-03-12 2010-09-30 Wyeth Llc ＰＫＮ３／ＲｈｏＣ高分子複合体およびその使用方法
GB0905972D0 (en) 2009-04-06 2009-05-20 Medical Res Council Antibodies against IL-17BR
EP3248618A1 (en) 2009-04-22 2017-11-29 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long rna molecules
JP2012524818A (ja) 2009-04-24 2012-10-18 バンダービルト ユニバーシティ 骨細胞機能および骨成長の抗ＴＧＦ−βによる誘導法
KR101721906B1 (ko) 2009-04-29 2017-03-31 애브비 바이오테크놀로지 리미티드 자동 주입 장치
CA2761310C (en) 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
GB0908425D0 (en) 2009-05-15 2009-06-24 Medical Res Council Medical use
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
EP2272979A1 (en) 2009-06-30 2011-01-12 Centre National de la Recherche Scientifique (CNRS) Method for testing a subject thought to be predisposed to having cancer
WO2011000543A1 (en) 2009-06-30 2011-01-06 Philochem Ag Murine antibody display library
EP2448599A1 (en) 2009-06-30 2012-05-09 Philogen S.p.A. Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
ES2640981T3 (es) 2009-08-05 2017-11-07 Philogen S.P.A. Selección como diana de neovasculatura de médula ósea
GB0914446D0 (en) 2009-08-18 2009-09-30 King S College London Bioconjugates and their uses in imaging
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
US20120263719A1 (en) 2009-10-22 2012-10-18 Yeda Research And Development Co., Ltd. Compositions and methods for treating aspergillosis
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
WO2011060272A2 (en) 2009-11-13 2011-05-19 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
TWI619521B (zh) 2009-12-15 2018-04-01 艾伯維生物技術有限責任公司 自動注射裝置、自動注射方法及防止不發射情況之方法
AU2010330907A1 (en) 2009-12-16 2012-06-14 Bosch, Phillip Methods of treating interstitial cystitis
KR20120105543A (ko) 2009-12-23 2012-09-25 4-안티바디 아게 인간 사이토메갈로바이러스에 대한 결합 멤버
US10429384B2 (en) 2010-01-22 2019-10-01 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
JP2013518590A (ja) 2010-02-02 2013-05-23 アボツト・バイオテクノロジー・リミテツド ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
EP4012714A1 (en) 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
CA3079122A1 (en) 2010-03-26 2011-09-29 Trustees Of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
WO2011125012A1 (en) 2010-04-05 2011-10-13 Wyeth Llc Biomarkers for p13k-driven cancer
BR112012026886B1 (pt) 2010-04-21 2020-11-24 Abbvie Biotechnology Ltd. dispositivo de injeção automático usável para distribuição controlada de agentes terapêuticos
US20110287018A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of Treating Interstitial Cystitis
GB201008541D0 (en) 2010-05-21 2010-07-07 Univ Geneve Diagnostic methods
DK2575884T3 (en) 2010-06-03 2018-09-03 Abbvie Biotechnology Ltd APPLICATIONS AND COMPOSITIONS TO TREAT HIDRADENITIS SUPPURATIVA (HS)
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
WO2011154705A1 (en) 2010-06-09 2011-12-15 Queen Mary & Westfield College Annexin 1 antibody
WO2011163401A2 (en) 2010-06-22 2011-12-29 Neogenix Oncology, Inc. Colon and pancreas cancer specific antigens and antibodies
PL3246044T3 (pl) 2010-08-23 2021-08-23 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
SG187953A1 (en) 2010-09-01 2013-03-28 Genzyme Corp Treatment of myocardial infarction using tgf - beta antagonists
ES2728282T3 (es) 2010-09-10 2019-10-23 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
EP2622091B1 (en) 2010-09-23 2019-03-13 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
GB201016864D0 (en) 2010-10-06 2010-11-17 Univ Aston Therapeutic methods
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
GB201019118D0 (en) 2010-11-11 2010-12-29 King S College Conjugates and their uses in molecular imaging
US8992908B2 (en) 2010-11-23 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
CN103415615B (zh) 2010-11-24 2015-11-25 高红 扩增造血干细胞
JP2014508511A (ja) 2010-12-20 2014-04-10 メドイミューン・リミテッド 抗ｉｌ−１８抗体およびそれらの使用
CN103547288B (zh) 2011-01-10 2016-03-16 密执安大学评议会 干细胞因子抑制剂
EP2667918B1 (en) 2011-01-24 2017-03-01 AbbVie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces
GB201102189D0 (en) 2011-02-08 2011-03-23 King S College London Materials and methods relating to cardiovascular imaging
PE20180776A1 (es) 2011-03-02 2018-05-07 Berg Llc Ensayos interrogatorios basados en celulas y usos de los mismos
JP2014513289A (ja) 2011-04-08 2014-05-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド ＩＦＮβに対する治療応答性を予測するバイオマーカーおよびその使用
MX345747B (es) 2011-04-21 2017-02-14 Abbvie Inc Dispositivo de inyección automático portable.
KR20140059168A (ko) 2011-04-21 2014-05-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 시신경 척수염 치료용 조성물 및 치료 방법
MX347514B (es) 2011-05-25 2017-04-28 Innate Pharma Sa Anticuerpos anti-receptores tipo inmunoglobulina citoliticos (kir) para el tratamiento de trastornos inflamatorios.
GB201109965D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating estrogen receptor alpher(ER) positive cancer
GB201109966D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating pten mutated or deficient cancer
SI2726094T1 (sl) 2011-06-28 2017-04-26 Oxford Biotherapeutics Ltd Terapevtski in diagnostični cilj
EP2732269B1 (en) 2011-07-12 2017-10-18 Epitomics, Inc. Facs-based method for obtaining an antibody sequence
EP2548891A1 (en) 2011-07-18 2013-01-23 Universiteit Maastricht Human monoclonal antibody against the gamma subunit of the acetylcholine receptor for use in the treatment of rhabdomyosarcoma.
WO2013014538A2 (en) 2011-07-25 2013-01-31 American University In Cairo Single-domain antibodies and graphene coated magnetic metal nanoparticles conjugate and methods for using the same
WO2013014149A1 (en) 2011-07-27 2013-01-31 Philogen S.P.A. Il-12 immunoconjugate
BR112014004162A2 (pt) 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
EP2748192B2 (en) 2011-08-23 2022-04-20 Foundation Medicine, Inc. Kif5b-ret fusion molecules and uses thereof
US10093705B2 (en) 2011-09-13 2018-10-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using FNDC5
EP2771349B1 (en) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
CN103906767A (zh) 2011-10-10 2014-07-02 米迪缪尼有限公司 对类风湿关节炎的治疗
AR088694A1 (es) 2011-11-17 2014-06-25 Pfizer Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
GB201121564D0 (en) 2011-12-14 2012-01-25 Queen Mary & Westfield College Use of antibody
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP3485906A1 (en) 2012-03-09 2019-05-22 Pfizer Inc Neisseria meningitidis compositions and methods thereof
MX365947B (es) 2012-03-27 2019-06-19 Genentech Inc Operaciones de cosecha mejoradas para proteinas recombinadas.
EP2834366A4 (en) 2012-04-02 2016-04-27 Berg Llc QUESTION-BASED ASSAYS AND USES THEREOF
WO2013173364A2 (en) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
NZ724892A (en) 2012-05-15 2018-04-27 Seattle Genetics Inc Self-stabilizing linker conjugates
WO2013192504A1 (en) 2012-06-22 2013-12-27 The Trustees Of Dartmouth College Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
WO2014020293A1 (en) 2012-07-31 2014-02-06 Imperial Innovations Limited Assay
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
ES2771324T3 (es) 2012-08-03 2020-07-06 Dana Farber Cancer Inst Inc Usos médicos de agentes que modulan la activación de las células inmunitarias y métodos de detección correspondientes
JP6368308B2 (ja) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
SG11201502404WA (en) 2012-10-03 2015-05-28 Philogen Spa Antigens associated with inflammatory bowel disease
KR20210063443A (ko) 2012-10-09 2021-06-01 바이오젠 엠에이 인코포레이티드 탈수초성 질환의 치료를 위한 복합 요법 및 용도
EP2906597B1 (en) 2012-10-15 2020-04-08 Medimmune Limited Antibodies to amyloid beta
EP2912459A2 (en) 2012-10-25 2015-09-02 Life Technologies Corporation Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins
CA2890207A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
PL2917195T3 (pl) 2012-11-05 2018-04-30 Pfizer Inc. Analogi spliceostatyny
CN104903351A (zh) 2012-11-07 2015-09-09 辉瑞公司 抗-notch3抗体及抗体-药物缀合物
EP2916835A4 (en) 2012-11-12 2016-07-27 Redwood Bioscience Inc COMPOUNDS AND METHOD FOR PRODUCING A CONJUGATE
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
KR20150085064A (ko) 2012-11-16 2015-07-22 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 단백질 화학적 변형을 위한 피크테 스펭글러 결합
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
EP2938633B1 (en) 2012-12-28 2018-02-07 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
EP2945652B1 (en) 2013-01-18 2021-07-07 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
CN105143470B (zh) 2013-02-28 2020-06-09 德克萨斯大学***董事会 用于将癌症分类为易感于tmepai定向疗法以及治疗所述癌症的方法
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
WO2014153056A2 (en) 2013-03-14 2014-09-25 Parkash Gill Cancer treatment using antibodies that bing cell surface grp78
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP2968550B1 (en) 2013-03-14 2018-11-14 Ffe Therapeutics LLC Compositions and methods for treating angiogenesis-related disorders
CA2906784C (en) 2013-03-15 2023-02-28 The Centre For Drug Research And Development Cytotoxic and anti-mitotic compounds, and methods of using the same
GB201308259D0 (en) 2013-05-08 2013-06-12 Iles Raymond K Cancer diagnosis and monitoring
AU2014275166B2 (en) 2013-06-06 2020-09-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
US9587032B2 (en) 2013-06-12 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University IgE antibodies for the inhibition of tumor metastasis
US9428748B2 (en) 2013-06-17 2016-08-30 Hong Gao Method of expanding hematopoietic stem cells
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
WO2015017529A2 (en) 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
KR20210002757A (ko) 2013-09-08 2021-01-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015050663A1 (en) 2013-10-01 2015-04-09 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of bim
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
GB201319374D0 (en) 2013-11-01 2013-12-18 Univ Nottingham Glycans as functional cancer targets abd antibodies thereto
GB201320061D0 (en) 2013-11-13 2013-12-25 Electrophoretics Ltd Materials nad methods for diagnosis and prognosis of liver cancer
CN105940115B (zh) 2013-11-15 2021-07-06 巴斯德研究所 恶性疟原虫青蒿素耐药性的分子标记物
CA2927806C (en) 2013-11-27 2023-01-10 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
EP3083670A2 (en) 2013-12-17 2016-10-26 Westfälische Wilhelms-Universität Münster Means and methods for treating a pruritus-like skin-disease
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
EP3082878B1 (en) 2013-12-19 2022-10-05 Seagen Inc. Methylene carbamate linkers for use with targeted-drug conjugates
EP2960252A1 (en) 2014-06-26 2015-12-30 Institut Pasteur Phospholipase for treatment of immunosuppression
SI3712174T1 (sl) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Protitelesa in delci proti VISTA
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
WO2015175340A1 (en) 2014-05-13 2015-11-19 Bavarian Nordic, Inc. Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
WO2015103026A2 (en) 2014-01-03 2015-07-09 The Regents Of The University Of Michigan Treatment of neurological disorders
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015110935A1 (en) 2014-01-27 2015-07-30 Pfizer Inc. Bifunctional cytotoxic agents
KR102448454B1 (ko) 2014-01-29 2022-09-28 다나-파버 캔서 인스티튜트 인크. Muc1-c/세포외 도메인 (muc1-c/ecd)에 대한 항체
KR102356951B1 (ko) 2014-02-11 2022-01-27 비스테라, 인크. 뎅기열 바이러스에 대한 항체 분자 및 그의 용도
EP3107557B1 (en) 2014-02-17 2021-06-09 Seagen Inc. Hydrophilic antibody-drug conjugates
US20170065702A1 (en) 2014-02-19 2017-03-09 Cangene Corporation Methods of modulating an immune response
GB201403815D0 (en) 2014-03-04 2014-04-16 Mologic Ltd Assay
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
AU2015243246B2 (en) 2014-04-10 2018-09-06 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
GB201407132D0 (en) 2014-04-23 2014-06-04 Velgene Biotechnology Marker for neurodegenerative disorders
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
WO2015179654A1 (en) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
EP3151830A4 (en) 2014-06-06 2018-02-07 Redwood Bioscience, Inc. Anti-her2 antibody-maytansine conjugates and methods of use thereof
WO2015191881A2 (en) 2014-06-11 2015-12-17 Green Kathy A Use of vista agonists and antagonists to suppress or enhance humoral immunity
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
CN113846062A (zh) 2014-07-25 2021-12-28 赛拉福柯蒂斯公司 用于嵌合抗原受体分子的调控表达的慢病毒载体
JP6698084B2 (ja) 2014-08-08 2020-05-27 オンコクエスト インコーポレイテッドＯｎｃｏｑｕｅｓｔ Ｉｎｃ． がんのチェックポイント干渉療法の成績を高めるための腫瘍抗原特異的抗体およびｔｌｒ３刺激
WO2016025202A1 (en) 2014-08-14 2016-02-18 The Regents Of The University Of Colorado Antibody-sirna conjugates and uses therefor
US11344620B2 (en) 2014-09-13 2022-05-31 Novartis Ag Combination therapies
PL3110447T3 (pl) 2014-09-16 2020-10-19 Synermore Biologics Co., Ltd. Przeciwciało anty-EGFR i jego zastosowania
US9879086B2 (en) 2014-09-17 2018-01-30 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
WO2016054555A2 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
AU2015333687B2 (en) 2014-10-14 2021-03-18 Dana-Farber Cancer Institute, Inc. Antibody molecules to PD-L1 and uses thereof
CA2959821A1 (en) 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
BR112017009297B1 (pt) 2014-11-05 2024-02-15 Annexon, Inc Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses
WO2016081455A1 (en) 2014-11-17 2016-05-26 Pelican Therapeutics, Inc. Human tnfrsf25 antibody
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
AU2015360903B2 (en) 2014-12-08 2021-03-25 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
WO2016092524A1 (en) 2014-12-11 2016-06-16 Inbiomotion S.L. Binding members for human c-maf
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
EP3244924B1 (en) 2015-01-15 2021-04-07 Oncoquest Pharmaceuticals Inc. Methods of increasing delivery of anti-cancer agents to targets
WO2016124558A1 (en) 2015-02-03 2016-08-11 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
MX2017010705A (es) 2015-02-19 2017-12-04 Pfizer Composiciones de neisseria meningitidis y metodos de la misma.
WO2016138312A2 (en) 2015-02-25 2016-09-01 Vanderbilt University Antibody-mediated neutralization of marburg virus
MX2017012102A (es) 2015-03-20 2018-01-12 Pfizer Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti.
EP3285811A1 (en) 2015-04-21 2018-02-28 Institut Gustave Roussy Therapeutic methods, products and compositions inhibiting znf555
CA2990360C (en) 2015-06-24 2024-02-13 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN116063481A (zh) 2015-09-04 2023-05-05 普里玛托普医疗股份有限公司 人源化抗-cd40抗体及其用途
AU2016335842A1 (en) 2015-10-07 2018-04-12 Obi Pharma, Inc. Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
CA3002676A1 (en) 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
JP6412906B2 (ja) 2015-11-03 2018-10-24 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 化合物、リンカー−薬物およびリガンド−薬物複合体
CN108350077A (zh) 2015-11-03 2018-07-31 糖模拟物有限公司 产生单克隆抗体、造血干细胞的方法和组合物以及利用所述抗体和造血干细胞的方法
WO2017079419A1 (en) 2015-11-05 2017-05-11 The Regents Of The University Of California Cells labelled with lipid conjugates and methods of use thereof
US11814440B2 (en) 2015-11-09 2023-11-14 The Children's Hospital Of Philadelphia Glypican 2 as a cancer marker and therapeutic target
EP3374391B1 (en) 2015-11-10 2024-04-17 Visterra, Inc. Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
GB201520583D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520592D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520589D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520543D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520542D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520544D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520565D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520603D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520546D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520575D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520558D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520563D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520579D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520564D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520595D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520567D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520597D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520545D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520562D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520570D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201604468D0 (en) 2016-03-16 2016-04-27 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607534D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520539D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520548D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017089786A1 (en) 2015-11-23 2017-06-01 Immunocore Limited Peptides
GB201520559D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520536D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520541D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520566D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520557D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607535D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017091683A1 (en) 2015-11-25 2017-06-01 Visterra, Inc. Antibody molecules to april and uses thereof
AU2016363013B2 (en) 2015-12-04 2022-03-10 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
JP2019502695A (ja) 2015-12-17 2019-01-31 ノバルティス アーゲー ＰＤ−１に対する抗体分子とＣ−Ｍｅｔ阻害剤との組合せおよびその使用
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
CN109152811A (zh) 2015-12-18 2019-01-04 阿吉尔瓦克斯公司 与xCT肽相关的组合物和方法
GB201601690D0 (en) 2016-01-29 2016-03-16 Heptares Therapeutics Ltd G proteins
JP2019507126A (ja) 2016-02-01 2019-03-14 ファイザー・インク ツブリシン類似体およびこれらの調製のための方法
EP3410849B1 (en) 2016-02-05 2023-07-05 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies
JP2019509993A (ja) 2016-02-12 2019-04-11 ヤンセン ファーマシューティカ エヌブイ 抗ｖｉｓｔａ（ｂ７ｈ５）抗体
CN109562154A (zh) 2016-03-10 2019-04-02 爱普瑞希斯有限公司 带有修饰hsp70域的抗原结合融合蛋白
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
TN2018000301A1 (en) 2016-03-14 2020-01-16 Univ Oslo Engineered immunoglobulins with altered fcrn binding
EP3429620A1 (en) 2016-03-15 2019-01-23 AstraZeneca AB Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
WO2017158436A1 (en) 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
AU2017238172A1 (en) 2016-03-21 2018-09-13 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
US20170274076A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulations of antibody molecules to dengue virus
KR20180134351A (ko) 2016-03-25 2018-12-18 시애틀 지네틱스, 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
CA3020848A1 (en) 2016-04-15 2017-10-19 Janssen Pharmaceuticals, Inc. Anti-human vista antibodies and use thereof
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
WO2017208018A1 (en) 2016-06-02 2017-12-07 Immunocore Limited Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
US10005843B2 (en) 2016-06-09 2018-06-26 Pelican Therapeutics, Inc. Anti-TNFRSF25 antibodies
US20190177438A1 (en) 2016-06-17 2019-06-13 Life Technologies Corporation Site-Specific Crosslinking of Antibodies
SI3472207T1 (sl) 2016-06-20 2021-04-30 F-Star Delta Limited Vezavne molekule, ki vežejo PD-L1 in LAG-3
JP7085708B2 (ja) 2016-06-20 2022-06-17 エフ－スター セラピューティクス リミテッド Ｌａｇ－３結合要素
WO2017221072A2 (en) 2016-06-21 2017-12-28 University Of Oslo Hla binding vaccine moieties and uses thereof
MX2019000327A (es) 2016-07-13 2019-04-11 Biogen Ma Inc Regímenes de dosificación de antagonistas de lingo-1 y usos para el tratamiento de trastornos desmielinizantes.
GB201613167D0 (en) 2016-07-29 2016-09-14 Univ Southampton Cancer and b-cell related disease therapy
CN110072887A (zh) 2016-08-02 2019-07-30 威特拉公司 工程化多肽及其应用
US11712480B2 (en) 2016-08-03 2023-08-01 Pfizer Inc. Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
EA201990222A1 (ru) 2016-08-05 2019-07-31 МЕДИММЬЮН, ЭлЭлСи Антитела к o2 и пути их применения
EA201990470A1 (ru) 2016-08-09 2019-09-30 Сиэтл Дженетикс, Инк. Конъюгаты лекарственного средства с самостабилизирующимися линкерами, имеющие улучшенные физико-химические свойства
EP3497237B1 (en) 2016-08-10 2022-05-04 Institut Pasteur Methods and reagents for detecting piperaquine-resistant plasmodium falciparum malaria
US11161909B2 (en) 2016-08-15 2021-11-02 Novartis Ag Regimens and methods of treating multiple sclerosis using ofatumumab
WO2018057955A1 (en) 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
US11638762B2 (en) 2016-10-18 2023-05-02 Seagen Inc. Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
KR20190064636A (ko) 2016-10-19 2019-06-10 메디뮨 엘엘씨 항-o1 항체 및 이의 용도
EP3535288A1 (en) 2016-11-07 2019-09-11 Immunocore Limited Peptides
JP6925431B2 (ja) 2016-11-09 2021-08-25 フィロジェン エッセ．ピー．アー． Ｉｌ２及びｔｎｆ突然変異体のイムノコンジュゲート
KR20190095946A (ko) 2016-12-23 2019-08-16 브리스톨-마이어스 스큅 컴퍼니 개선된 바이오분석 및 바이오프로세싱 성질을 위한 치료용 면역글로불린 g4의 디자인
JP7139332B2 (ja) 2016-12-23 2022-09-20 ノバルティス アーゲー 第ｘｉ因子抗体および使用方法
JP7360324B2 (ja) 2016-12-23 2023-10-12 ビステラ， インコーポレイテッド 結合ポリペプチドおよびそれを作製する方法
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
CN110431150A (zh) 2017-01-18 2019-11-08 威特拉公司 抗体分子-药物偶联物及其用途
AU2018211561B2 (en) 2017-01-24 2020-04-30 Pfizer Inc. Calicheamicin derivatives and antibody drug conjugates thereof
IL303108B1 (en) 2017-01-31 2024-03-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor
US20180221476A1 (en) 2017-02-06 2018-08-09 Oncoquest Nc. Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
JP7116736B2 (ja) 2017-03-02 2022-08-10 ノバルティス アーゲー 操作されたヘテロ二量体タンパク質
CN110582278B (zh) 2017-03-10 2023-04-18 伊姆贝拉神经疗法公司 药物组合物及其用途
JP2020512312A (ja) 2017-03-24 2020-04-23 シアトル ジェネティックス， インコーポレイテッド グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体
WO2018176019A1 (en) 2017-03-24 2018-09-27 The Regents Of The University Of California Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
KR20200020662A (ko) 2017-04-03 2020-02-26 온콜로지, 인크. 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
WO2018195283A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
SG11201909563VA (en) 2017-04-27 2019-11-28 Seattle Genetics Inc Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201047A1 (en) 2017-04-28 2018-11-01 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
EP3630836A1 (en) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
US11390666B2 (en) 2017-06-07 2022-07-19 Philogen S.P.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
WO2018237157A1 (en) 2017-06-22 2018-12-27 Novartis Ag CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF
EP3431496A1 (en) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti- isoasp7 amyloid beta antibodies and uses thereof
CA3070095A1 (en) 2017-07-20 2019-01-24 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
KR20200058540A (ko) 2017-10-02 2020-05-27 비스테라, 인크. Cd138에 대한 항체 분자 및 이의 용도
EP3461841B1 (en) 2017-10-02 2019-09-11 Certest Biotec, S.L. Anti-dps antibodies and test devices for the detection of bacteria of the genus campylobacter
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CN111655725A (zh) 2017-10-19 2020-09-11 德比奥药物国际股份有限公司 用于治疗癌症的组合产品
US20200283485A1 (en) 2017-10-20 2020-09-10 Institut Curie Hook fusion protein for regulating the cellular trafficking of a target protein
EP3697809A1 (en) 2017-10-20 2020-08-26 Institut Curie Dap10/12 based cars adapted for rush
AU2018364630A1 (en) 2017-11-09 2020-05-21 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
EP3720881A1 (en) 2017-12-08 2020-10-14 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
EP3502139A1 (en) 2017-12-19 2019-06-26 Philogen S.p.A. Antibodies to tumour antigens
WO2019121906A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Specific pd-l1 binding sequences inserted in a ch3 domain
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
KR20200122351A (ko) 2018-02-20 2020-10-27 시애틀 지네틱스, 인크. 소수성 아우리스타틴 f 화합물 및 그의 접합체
EP3530282A1 (en) 2018-02-27 2019-08-28 Diaccurate Therapeutic methods
US20210238280A1 (en) 2018-03-14 2021-08-05 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3765516A2 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
EP3785732A4 (en) 2018-04-24 2022-02-23 Ampsource Biopharma Shanghai Inc. ANTIBODIES AGAINST TIM-3 AND USE THEREOF
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
GB201808927D0 (en) 2018-05-31 2018-07-18 Institute Of Cancer Res Royal Cancer Hospital Materials and methods for monitoring the development of resistance of cancers to treatment
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
TW202015740A (zh) 2018-06-07 2020-05-01 美商西雅圖遺傳學公司 喜樹鹼結合物
WO2019246293A2 (en) 2018-06-19 2019-12-26 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
TW202016144A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
AU2019301206A1 (en) 2018-07-12 2021-03-04 F-Star Therapeutics Limited Antibody molecules that bind CD137 and OX40
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
CN112423845A (zh) 2018-07-12 2021-02-26 F星贝塔有限公司 结合pd-l1和cd137的抗体分子
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
US20220242957A1 (en) 2018-09-27 2022-08-04 Marengo Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
CA3113818A1 (en) 2018-10-05 2020-04-09 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
BR112021009856A8 (pt) 2018-11-20 2021-09-08 Bavarian Nordic As Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l
EP3898686A1 (en) 2018-12-20 2021-10-27 Novartis AG Pharmaceutical combinations
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
EP3693063A1 (en) 2019-02-06 2020-08-12 Diaccurate Methods and compositions for treating cancer
EP3924739A1 (en) 2019-02-12 2021-12-22 Biogen MA Inc. Biomarkers of progressive multifocal leukoencephalopathy
KR20210125034A (ko) 2019-02-15 2021-10-15 우시 바이올로직스 아일랜드 리미티드 동질성이 개선된 항체-약물 콘쥬게이트의 제조방법
AU2020223293A1 (en) 2019-02-15 2021-08-19 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
WO2020168024A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
CN114026122A (zh) 2019-02-21 2022-02-08 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
CN114126714A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 抗tcr抗体分子及其用途
JP2022521937A (ja) 2019-02-21 2022-04-13 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
JP2022521750A (ja) 2019-02-21 2022-04-12 マレンゴ・セラピューティクス，インコーポレーテッド カルレティキュリンに結合する多機能性分子およびその使用
CA3130628A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
MX2021011830A (es) 2019-03-29 2022-01-24 Atarga Llc Anticuerpo anti fgf23.
GB201906578D0 (en) 2019-05-09 2019-06-26 Cancer Research Tech Ltd Detection of fusion protein
SG11202112223XA (en) 2019-05-10 2021-12-30 Takeda Pharmaceuticals Co Antibody drug conjugates
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
US20230071196A1 (en) 2019-05-21 2023-03-09 Novartis Ag Variant cd58 domains and uses thereof
WO2020257289A2 (en) 2019-06-17 2020-12-24 Visterra, Inc. Humanized antibody molecules to cd138 and uses thereof
GB201909393D0 (en) 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
EP3999091A1 (en) 2019-07-15 2022-05-25 MedImmune Limited Tripartite systems for protein dimerization and methods of use
CN114555807A (zh) 2019-07-19 2022-05-27 费城儿童医院 包含磷脂酰肌醇蛋白聚糖2结合结构域的嵌合抗原受体
EP4004025A1 (en) 2019-07-26 2022-06-01 Visterra, Inc. Interleukin-2 agents and uses thereof
GB201910899D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Binding members
GB201912030D0 (en) 2019-08-21 2019-10-02 Cancer Research Tech Ltd Binding molecules
GB201912657D0 (en) 2019-09-03 2019-10-16 Scancell Ltd Binding members
GB201912882D0 (en) 2019-09-06 2019-10-23 Scancell Ltd Ssea-4 binding members
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
MX2022003268A (es) 2019-09-19 2022-06-02 Seagen Inc Liberacion selectiva de farmaco a partir de conjugados internalizados de compuestos biologicamente activos.
KR20220079606A (ko) 2019-10-04 2022-06-13 씨젠 인크. 캄프토테신 펩티드 접합체
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
GB201915163D0 (en) 2019-10-18 2019-12-04 Univ Southampton Cancer vaccine
EP4048285A1 (en) 2019-10-21 2022-08-31 Novartis AG Tim-3 inhibitors and uses thereof
TW202128166A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 組合療法
EP4061406A1 (en) 2019-11-20 2022-09-28 Bavarian Nordic A/S Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer
CA3165399A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics Inc CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES
TW202140553A (zh) 2020-01-13 2021-11-01 美商威特拉公司 C5ar1抗體分子及其用途
BR112022012310A2 (pt) 2020-01-17 2022-09-06 Novartis Ag Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
CA3168882A1 (en) 2020-02-25 2021-09-02 Mediboston, Inc. Camptothecin derivatives and conjugates thereof
US20210311054A1 (en) 2020-04-01 2021-10-07 Institut Pasteur Severe acute respiratory syndrome (sars) - associated coronavirus diagnostics
US11815513B2 (en) 2020-04-01 2023-11-14 Institut Pasteur Severe acute respiratory syndrome (SARS)-associated coronavirus diagnostics
WO2021203024A1 (en) 2020-04-03 2021-10-07 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
BR112022020332A2 (pt) 2020-04-10 2022-12-13 Seagen Inc Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune
WO2021209824A1 (en) 2020-04-17 2021-10-21 Institut Pasteur Methods and products for serological analysis of sars-cov-2 infection
GB202005779D0 (en) 2020-04-21 2020-06-03 Scancell Ltd Anti-tumour immune responses
EP4143236A1 (en) 2020-05-01 2023-03-08 Novartis AG Engineered immunoglobulins
US20230167193A1 (en) 2020-05-01 2023-06-01 Novartis Ag Immunoglobulin variants
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods
CN115803062A (zh) 2020-06-03 2023-03-14 博泰康医药公司 滋养层细胞表面抗原2(trop-2)抗体
EP4172206A1 (en) 2020-06-24 2023-05-03 Visterra, Inc. Antibody molecules to april and uses thereof
US20230256114A1 (en) 2020-07-07 2023-08-17 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
WO2022008976A1 (en) 2020-07-10 2022-01-13 Institut Pasteur Use of gdf11 to diagnose and treat anxiety and depression
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
KR20230074144A (ko) 2020-08-26 2023-05-26 마렝고 테라퓨틱스, 인크. NKp30에 결합하는 항체 분자 및 이의 용도
EP4204458A1 (en) 2020-08-26 2023-07-05 Marengo Therapeutics, Inc. Methods of detecting trbc1 or trbc2
AU2021331075A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4214223A1 (en) 2020-09-21 2023-07-26 Theravectys High throughput methods and products for sars-cov-2 sero-neutralization assay
TW202229312A (zh) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
IL302412A (en) 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
PE20231947A1 (es) 2020-11-09 2023-12-05 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco
GB202018395D0 (en) 2020-11-23 2021-01-06 Scancell Ltd Immunotherapy
EP4255466A1 (en) 2020-12-04 2023-10-11 Visterra, Inc. Methods of using interleukin-2 agents
WO2022153195A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
EP4277664A1 (en) 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
BR112023014128A2 (pt) 2021-01-15 2023-10-31 Seagen Inc Conjugados de anticorpo-fármaco imunomodulatórios
US20220226442A1 (en) 2021-01-20 2022-07-21 Visterra, Inc. Interleukin-2 agents and uses thereof
EP4284510A1 (en) 2021-01-29 2023-12-06 Novartis AG Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
CA3206244A1 (en) 2021-02-03 2022-08-11 Kung-Pern WANG Immunostimulatory compounds and conjugates
WO2022182872A2 (en) 2021-02-24 2022-09-01 Alladapt Immunotherapeutics, Inc. Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
CA3213625A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
KR20240015670A (ko) 2021-05-28 2024-02-05 씨젠 인크. 안트라사이클린 항체 접합체
KR20240025597A (ko) 2021-06-29 2024-02-27 씨젠 인크. 비푸코실화 항-cd70 항체 및 cd47 길항제의 조합으로 암을 치료하는 방법
AU2022334794A1 (en) 2021-08-25 2024-03-28 Iontas Limited Preparation of libraries of protein variants expressed in eukaryotic cells
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
US20230183358A1 (en) 2021-11-10 2023-06-15 Astrazeneca Ab Antibody molecules and conjugates
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023097254A1 (en) 2021-11-24 2023-06-01 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
WO2023102463A1 (en) 2021-12-01 2023-06-08 Visterra, Inc. Methods of using interleukin-2 agents
GB202117928D0 (en) 2021-12-11 2022-01-26 Cancer Research Tech Ltd Immunotherapy for cancer
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
TW202342548A (zh) 2022-02-07 2023-11-01 美商威特拉公司 抗獨特型(anti-idiotype)抗體分子及其用途
WO2023170434A1 (en) 2022-03-11 2023-09-14 Macomics Limited Compositions and methods for modulation of macrophage activity
TW202400137A (zh) 2022-03-17 2024-01-01 美商思進公司 喜樹鹼偶聯物
US20240092921A1 (en) 2022-04-25 2024-03-21 Visterra, Inc. Antibody molecules to april and uses thereof
WO2023215740A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory antibody-drug conjugates
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023223092A1 (en) 2022-05-18 2023-11-23 Institut Pasteur Identification of a human circovirus
WO2023240287A1 (en) 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
EP4296279A1 (en) 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin (ttr) binding proteins and uses thereof
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20240108744A1 (en) 2022-07-27 2024-04-04 Mediboston Limited Auristatin derivatives and conjugates thereof
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
WO2024030577A1 (en) 2022-08-03 2024-02-08 Seagen Inc. Immunostimulatory anti-pd-l1-drug conjugates
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
WO2024042104A1 (en) 2022-08-26 2024-02-29 Merck Patent Gmbh Combination cancer treatment comprising an anti-msln/cd137 antibody and pd-1/pd-l1 inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0125023B1 (en) * 1983-04-08 1991-06-05 Genentech, Inc. Recombinant immunoglobulin preparations, methods for their preparation, dna sequences, expression vectors and recombinant host cells therefor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645738A (en) * 1983-09-30 1987-02-24 Memorial Sloan-Kettering Institute Cancer Center Method for differential diagnosis of T cell leukemias using monoclonal antibodies
US4731244A (en) * 1985-11-13 1988-03-15 Ortho Pharmaceutical Corporation Monoclonal antibody therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125023B1 (en) * 1983-04-08 1991-06-05 Genentech, Inc. Recombinant immunoglobulin preparations, methods for their preparation, dna sequences, expression vectors and recombinant host cells therefor
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6344897A (ja) * 1986-04-14 1988-02-25 Dai Ichi Seiyaku Co Ltd ペプチド類の生産法
JPS6336786A (ja) * 1986-07-31 1988-02-17 Teijin Ltd 抗体ｌ鎖発現型核酸塩基配列，プラスミド，細胞及びキメラ抗体ｌ鎖
JPS6336796A (ja) * 1986-08-01 1988-02-17 Teijin Ltd マウス−ヒトキメラ抗体、それをコ−ドする発現型キメラｄｎａ配列、プラスミド及び細胞
JP2008509084A (ja) * 2004-05-11 2008-03-27 アブゲノミクス コーポレイション Ｔ細胞死誘導エピトープ

Also Published As

Publication number Publication date
US4935496A (en) 1990-06-19
EP0184187B1 (en) 1992-06-03
EP0184187A3 (en) 1987-12-23
EP0184187A2 (en) 1986-06-11

Similar Documents

Publication Publication Date Title
JPS61134325A (ja) ハイブリツド抗体遺伝子の発現方法
US5258498A (en) Polypeptide linkers for production of biosynthetic proteins
EP0327378B1 (en) Domain-modified constant region antibodies
JP3559795B2 (ja) 組換免疫グロブリンの調製方法
FI79120B (fi) Fusionerad gen och foerfarande foer framstaellning av ett terapeutiskt anvaendbart hybridprotein.
US6207804B1 (en) Genetically engineered antibody analogues and fusion proteins thereof
JP2781459B2 (ja) ヒト血清アルブミンのｎ―末端フラグメント含有融合蛋白質
AU634314B2 (en) Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
KR100244677B1 (ko) 촉매 항체 성분
JPH0645640B2 (ja) 雑種ｄｎａおよびそれにより調製される結合性組成物
JP2000157291A (ja) 大きな構造遺伝子の製造および発現
AU4402189A (en) Production of chimeric mouse-human antibodies with specificity to human tumor antigens
JPH05500310A (ja) 融合蛋白質の製造方法
JPS58219199A (ja) 外来性蛋白質発現用クロ−ニングベクタ−
JPH03505279A (ja) インターロイキン―１インヒビター
JPH02501263A (ja) ヒトの組織因子のクローニングと形質発現
US5658753A (en) Catalytic antibody components
US5101024A (en) Human immunoglobulin and enhancer gene fragments
JPS62153300A (ja) ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
JPS63304987A (ja) アンギオゲニン類の遺伝子工学産生方法
JPS6156078A (ja) 酵母を宿主とする分泌発現ベクタ−
EP0217916A1 (en) Hybrid-gene cassette vector
JPH0440894A (ja) イヌ免疫グロブリンγ鎖の定常領域をコードする遺伝子断片およびマウス×イヌキメラ抗体
JP2009528816A (ja) 核酸切断剤
JPH0698021B2 (ja) マウス−ヒトキメラ抗体、それをコ−ドする発現型キメラｄｎａ配列、プラスミド及び細胞